Erasca
eras was generally well tolerated with primarily grade or observed | Erasca
Company
Deck Type
Sector
Industry
Deck date
August 2023
Slide
30 of 56
Similar slides by Erasca
See diffirences between slides (animation)
Investor Presentation
January 2024
eras was generally well tolerated with primarily grade or observed | Erasca
Investor Presentation
November 2023
eras was generally well tolerated with primarily grade or observed | Erasca
Related slides by other companies
Nuvalent
Investor Presentation
February 2024
preliminary safety profile favorable and consistent with alk selective sparing design of phase treatment related adverse events in patients all treated patients has not been identified transient asymptomatic grade increase infrequent requiring dose modification discontinued due to dose reduced due to overall avoiding related any alt increased ast increased nausea constipation fatigue peripheral edema grade grade grade any grade resulting in treat resulting in dose reduced dose for source lin grade alt ast elevation grade nausea cognitive disturbance grade elevation grade treatment continues at the city treatment related adverse event at from | Nuvalent
Nuvalent
Investor Presentation
January 2024
preliminary safety profile favorable and consistent with alk selective sparing design of phase has not been identified transient asymptomatic grade increase treatment related adverse events in patients all treated patients grade grade grade any grade infrequent requiring dose any modification discontinued due to dose reduced due to overall avoiding related alt increased ast increased nausea constipation fatigue peripheral edema data cut off alt alanine ast aspartate creatinine dose limiting toxicity treatment related adverse event resulting in treatment discontinuation were grade alt grade ast elevations intolerable grade constipation occurred at following dose increase from resulting in dose reduction were grade alt ast elevation grade alt ast elevation grade nausea cognitive disturbance grade elevation grade treatment continues at the reduced dose for these patients source lin on | Nuvalent
Nuvalent
Investor Presentation
April 2024
preliminary safety profile favorable and consistent with alk selective sparing design of phase treatment related adverse events in patients all treated patients has not been identified transient asymptomatic grade increase infrequent requiring dose modification discontinued due to dose reduced due to overall avoiding related any alt increased ast increased i nausea constipation fatigue peripheral edema grade grade grade any grade reduced dose for source lin a creatinine dose limiting toxicity treatment related adverse event intolerable at from grade alt ast elevation grade nausea cognitive disturbance grade elevation grade treatment continues at the | Nuvalent
Nuvalent
Investor Presentation
April 2024
preliminary safety profile favorable and consistent with the highly selective sparing design of phase treatment related adverse events in patient all treated patients no no treatment related no aes leading to dose reduction or discontinuation no treatment related fatigue alt increased ast increased myalgia grade grade any grade grade ses alt aint as aspartate source a doe serous ses i | Nuvalent
Other recent decks by Erasca
See all presentations (4 decks)
Investor Presentation
January 2024
Investor Presentation
November 2023
IPO
July 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io